Regulation and kinetics of platelet-activating factor and leukotriene C4 synthesis by activated human basophils

Clinical and Experimental Allergy

Volumn 33, Issue 8, 2003, Pages 1125-1134

  Lie, W J ^a   Homburg, C H E ^a   Kuijpers, T W ^a   Knol, E F ^b   Mul, F P J ^a   Roos, D ^a   Tool, A T J ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Dept of Exp Immunohematology ^*  (Netherlands)

Author keywords

cPLA2; Human basophils; LTC4; PAF

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALLERGEN; BLOCKING AGENT; CALCIUM ION; COMPLEMENT COMPONENT C5A; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 3; LEUKOTRIENE C4; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPASE A2 INHIBITOR; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; BASOPHIL; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOSOL; ENZYME KINETICS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PURIFICATION; SARCOPLASMIC RETICULUM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARACHIDONIC ACIDS; BASOPHILS; CELLS, CULTURED; COMPLEMENT C5A; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-3; LEUKOTRIENE C4; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; PHOSPHONIC ACIDS; PLATELET ACTIVATING FACTOR; RECEPTORS, IGE; RECOMBINANT PROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 0042622595     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01726.x     Document Type: Article

References (52)

1. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-55.
2. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152:897-905.
3. Coleman RA, Eglen RM, Jones RL et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 1995; 23:283-5.
4. Samuelsson B, Dahlen S, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-6.
5. Ayala A, Chaudry IH. Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 1996; 4:265-75.
6. 4, and histamine in normal human subjects. Thorax 1984; 39:500-4.
7. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991; 144:1053-7.
8. Hui KP, Taylor IK, Taylor GW et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-9.
9. Rodriguez Roisin R. Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Eur Respir J 1997; 10:1359-71.
10. Chilton FH, Averill FJ, Hubbard WC, Fonteh AN, Triggiani M, Liu MC. Antigen-induced generation of lyso-phospholipids in human airways. J Exp Med 1996; 183:2235-45.
11. 2 into nasal fluids after allergenic challenge: possible role in the regulation of platelet activating factor release. J Allergy Clin Immunol 1994; 94:109-19.
12. Miwa M, Miyake T, Yamanaka T et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1998; 82:1983-91.
13. 2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997; 22:1-2.
14. 4 release in human basophils. J Allergy Clin Immunol 1998; 102:512-20.
15. Gibbs BF, Grabbe J. Inhibitors of PI 3-kinase and MEK differentially affect mediator secretion from immunologically activated human basophils. J Leukoc Biol 1999; 65:883-90.
16. Miura K, Schroeder JT, Hubbard WC, MacGlashan DW Jr. Extracellular signal-regulated kinases regulate leukotriene C4 generation, but not histamine release of IL-4 production from human basophils. J Immunol 1999; 162:4198-206.
17. 4 generation in human basophils: difference in characteristics between acute and late priming effects. J Immunol 2000; 164:3026-34.
18. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997; 272:16709-12.
19. Clark JD, Lin LL, Kriz RW et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 1991; 65:1043-51.
20. Sharp JD, White DL, Chiou XG et al. Molecular cloning and expression of human Ca(2+)-sensitive cytosolic phospholipase A2. J Biol Chem 1991; 266:14850-3.
21. Lie WJ, Mul FP, Roos D, Verhoeven AJ, Knol EF. Degranulation of human basophils by picomolar concentrations of IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1998; 101:683-90.
22. MacGlashan DW, Peters SP, Warner J, Lichtenstein LM. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol 1986; 136:2231-9.
23. Warner JA, Peters SP, Lichtenstein LM, Hubbard W et al. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J Leukoc Biol 1989; 45:558-71.
24. Miadonna A, Leggieri E, Tedeschi A et al. Cord blood basophil releasability: evaluation of histamine release and leukotriene C4 generation. Int Arch Allergy Appl Immunol 1998; 86:42-7.
25. Dahinden CA, Kurimoto J, Baggiolini M, Dewald B, Walz A. Histamine and sulfidoleukotriene release from human basophils: different effects of antigen, anti-IgE, C5a, f-Met-Leu-Phe and the novel neutrophil-activating peptide NAF. Int Arch Allergy Appl Immunol 1989; 90:113-8.
26. Ochensberger B, Tassera L, Bifrare D, Rihs S, Dahinden CA. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur J Immunol 1999; 29:11-22.
27. Betz SJ, Lotner GZ, Henson PM. Generation and release of platelet-activating factor (PAF) from enriched preparations of rabbit basophils; failure of human basophils to release PAF. J Immunol 1980; 125:2749-55.
28. Sanchez-Crespo M, Alonso F, Egido J. Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during the stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. Immunology 1980; 40:645-55.
29. Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 1981; 42:191-9.
30. Camussi G, Tetta C, Coda R, Benveniste J. Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus. Lab Invest 1981; 44:241-51.
31. Street IP, Lin HK, Laliberte F et al. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry 1993; 32:5935-40.
32. Lio YC, Reynolds LJ, Balsinde J, Dennis EA. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochem Biophys Acta 1996; 1302:55-60.
33. Boer de M, Roos D. Metabolic comparison between basophils and other leucocytes from human blood. J Immunol 1986; 136:3447-54.
34. Mul FPJ, Knol EF, Roos D. An improved method for the purification of basophilic granulocytes from human blood. J Immunol Methods 1992; 149:207-14.
35. Gilbert HS, Ornstein L. Basophil counting with a new staining method using Alcian blue. Blood 1975; 46:279-86.
36. Henderson WR, Jorg A, Klebanoff SJ. Eosinophil peroxidase-mediated inactivation of leukotrienes B4, C4, and D4. J Immunol 1982; 128:2609-13.
37. Wei YF, Heghinian K, Bell RL, Jakschik BA. Contribution of macrophages to immediate hypersensitivity reaction. J Immunol 1986; 137:1993-2000.
38. Tool ATJ, Koenderman L, Kok PTM, Blom M, Roos D, Verhoeven AJ. Release of platelet-activating factor is important for the respiratory burst induced in human eosinophils by opsonized particles. Blood 1992; 10:2729-32.
39. Siraganian RP. Refinements in the automated fluorometric histamine analysis system. J Immunol Methods 1975; 7:283-90.
40. Knol EF, Koenderman L, Mul FPJ, Verhoeven AJ, Roos D. Differential activation of human basophils by anti-IgE and formylmethionyl-leucyl-phenylalanine. Indications for protein kinase C-dependent and -independent activation pathways. Eur J Immunol 1991; 21:881-5.
41. Blom M, Tool ATJ, Wever PC et al. Human eosinophils express, relative to other circulating leukocytes, large amounts of secretory 14-kD phospholipase A2. Blood 1998; 91:3037-43.
42. Nakajima K, Murakami M, Yanoshita R et al. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J Biol Chem 1997; 272:19708-13.
43. Fonteh AN, Chilton FH. Mobilization of different arachidonate pools and their roles in the generation of leukotrienes and free arachidonic acid during immunologic activation of mast cells. J Immunol 1993; 150:563-70.
44. Triggiani M, Schleimer RP, Warner JA, Chilton FH. Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J Immunol 1991; 147:660-6.
45. Akasaka R, Teshima R, Ikebuchi H, Sawada J. Effects of three different Ca(2+)-ATPase inhibitors on Ca2+ response and leukotriene release in RBL-2H3 cells. Inflamm Res 1996; 45:583-9.
46. 4 production in leukemic basophils. Prostaglandins 1987; 34:29-40.
47. Amon U, Von Stebut E, Von Gizycki U, Wolff HH. Control function of protein kinase C isozymes on leukotriene generation from human basophils. Agents Actions 1994; 41 (Suppl. C):C9-C10.
48. Brunner T, De Weck AL, Dahinden CA. Platelet-activating factor induces mediator release by human basophils primed with IL-3, granulocyte-macrophage colony-stimulating factor, or IL-5. J Immunol 1991; 147:237-42.
49. Fonteh AN. Differential effects of arachidonoyl trifluoromethyl ketone on arachidonic acid release and lipid mediator biosynthesis by human neutrophils. Eur J Biochem 2002; 269:3760-70.
50. Uozumi N, Kume K, Nagase T et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997; 390:618-22.
51. Hundley TR, Marshall LA, Hubbard WC, MacGlashan DW Jr. Characteristics of arachidonic acid generation in human basophils: relationship between the effects of inhibitors of secretory phospholipase A2 activity and leukotriene C4 release. J Pharmacol Exp Ther 1998; 284:847-57.
52. 2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol 1994; 152:5438-46.